Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

What's Three FDA Rejections Worth? For Pain Therapeutics CEO: $23 Million

What's Three FDA Rejections Worth? For Pain Therapeutics CEO: $23 Million

Failure is very profitable for Pain Therapeutics CEO Remi Barbier.

Biotech School: How to Spot Hidden Danger Signs in Clinical Trial Data

Biotech School: How to Spot Hidden Danger Signs in Clinical Trial Data

Using Northwest Bio as an example, I'm going to teach you how to read clinical trial data to find red flags and bad stuff biotechs don't want you to see.

Axovant Sinks on Rival's Alzheimer's Drug Setback

Axovant Sinks on Rival's Alzheimer's Drug Setback

An Alzheimer's drug under development by Danish pharma Lundbeck failed a pivotal phase III study and Axovant suffered collateral damage.

Cloudy Outlook for Aerie Pharma's Glaucoma Drug

Cloudy Outlook for Aerie Pharma's Glaucoma Drug

When an experimental glaucoma drug is only marginally effective, one way to produce positive clinical trial results is to enroll patients with borderline glaucoma.

Biotech Stock Mailbag: Sarepta Therapeutics Approval Edition

Biotech Stock Mailbag: Sarepta Therapeutics Approval Edition

TheStreet's Adam Feuerstein answers reader questions about Sarepta Therapeutics and its newly approved drug Exondys 51 for Duchenne muscular dystrophy.